Evidence map›Paper›PMID 11524593›Full record

ArticleAnnals of surgery2001

Clinical intestinal transplantation: a decade of experience at a single center.

K Abu-Elmagd, J Reyes, G Bond, G Mazariegos, T Wu, N Murase, R Sindhi, D Martin, J Colangelo, M Zak and 8 more

Open access · greenAbstract readComparative Study
In one paragraph

Article in Annals of surgery, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
29.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 375 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Update on Maintenance Immunosuppression in Intestinal Transplantation.Gastroenterology clinics of North America · 2024
    Review
  4. Chimerism-Mediated Tolerance in Intestinal Transplantation.Gastroenterology clinics of North America · 2024
    Review
  5. Review
  6. Review
  7. Liver Inclusion Appears to Be Protective Against Graft Loss-Due-to Chronic But Not Acute Rejection Following Intestinal Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2023
    Article
  8. Article
  9. Review
  10. Article
  11. Transplant Critical Care: Is there a Need for Sub-specialized Units? - A Perspective.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2018
    Article
  12. Article
  13. Review
  14. Article
  15. The concept of gut rehabilitation and the future of visceral transplantation.Nature reviews. Gastroenterology & hepatology · 2015
    Review
  16. Review
  17. India's first successful intestinal transplant: the road traveled and the lessons learnt.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2014
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

K Abu-ElmagdThomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA. kae@med.pitt.edu
J Reyes
G Bond
G Mazariegos
T Wu
N Murase
R Sindhi
D Martin
J Colangelo
M Zak
D Janson
M Ezzelarab
I Dvorchik
M Parizhskaya
M Deutsch
A Demetris
J Fung
T E Starzl
University of Pittsburgh · USUniversity of Pittsburgh Medical Center · US

Funding

MODULATION OF CHIMERISM FOR INTESTINAL TRANSPLANTATIONR01DK054232 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MURASE, NORIKO · 1999 to 2003
$2.3M
ORTHOTOPIC LIVER TRANSPLANTATIONR01DK029961 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI STARZL, THOMAS E · 1986 to 2001
$876k
ORTHOTOPIC LIVER TRANSPLANTATIONR37DK029961 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI STARZL, THOMAS E · 1988 to 1995
–
NIDDK NIH HHS DK-29961NIDDK NIH HHS R01 DK054232NIDDK NIH HHS R01 DK54232
6 · The paper itself

Abstract

objectiveTo assess the long-term efficacy of intestinal transplantation under tacrolimus-based immunosuppression and the therapeutic benefit of newly developed adjunct immunosuppressants and management strategies. SUMMARY BACKGROUND DATA: With the advent of tacrolimus in 1990, transplantation of the intestine began to emerge as therapy for intestinal failure. However, a high risk of rejection, with the consequent need for acute and chronic high-dose immunosuppression, has inhibited its widespread application.

methodsDuring an 11-year period, divided into two segments by a 1-year moratorium in 1994, 155 patients received 165 intestinal allografts under immunosuppression based on tacrolimus and prednisone: 65 intestine alone, 75 liver and intestine, and 25 multivisceral. For the transplantations since the moratorium (n = 99), an adjunct immunosuppressant (cyclophosphamide or daclizumab) was used for 74 transplantations, adjunct donor bone marrow was given in 39, and the intestine of 11 allografts was irradiated with a single dose of 750 cGy.

resultsThe actuarial survival rate for the total population was 75% at 1 year, 54% at 5 years, and 42% at 10 years. Recipients of liver plus intestine had the best long-term prognosis and the lowest risk of graft loss from rejection (P =.001). Since 1994, survival rates have improved. Techniques for early detection of Epstein-Barr and cytomegaloviral infections, bone marrow augmentation, the adjunct use of the interleukin-2 antagonist daclizumab, and most recently allograft irradiation may have contributed to the better results.

conclusionThe survival rates after intestinal transplantation have cumulatively improved during the past decade. With the management strategies currently under evaluation, intestinal transplant procedures have the potential to become the standard of care for patients with end-stage intestinal failure.

Indexed as

AdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedChildChild, PreschoolCyclophosphamideDaclizumabGraft SurvivalGraft vs Host DiseaseHumansImmunoglobulin GImmunosuppression TherapyIntestinesLiver TransplantationMonitoring, ImmunologicPrednisoneAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCyclophosphamideDaclizumabImmunoglobulin GPrednisoneTacrolimus

Identifiers

PMID11524593
PMCPMC1422031
OpenAlexW2012720158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.